Invenomic Capital Management LP Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001769456
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q4 2025 · 147 positions · Total reported value $2.15B · Top-10 concentration 24.9% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 66.9% · 35 new · 31 cut · 35 exited
Active Share (vs S&P 500): 99.0% · vs QQQ: 99.1% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): +2.7% · vs SPY +0.6% · Prev Value $1.67B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): +8.2% · vs SPY +6.1% · Latest Value $2.02B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q4 2025 13F filing, Invenomic Capital Management LP disclosed 147 equity positions with a combined reported value of $2.15B. The filing implies a diversified portfolio: its ten largest positions account for 24.9% of reported value. HoldingsHub classifies the profile as Mid / Diversified / High Turnover.
The largest disclosed positions as of Q4 2025 were VTRS ($69.64M), GPN ($61.73M), XRAY ($58.66M). By sector, the heaviest allocations are Consumer Discretionary 30.1%, Technology 17.5%. Versus the prior quarter, allocation shifted toward Consumer Discretionary (+6.5pp), Industrials (+3.8pp) and away from Health Care (-1.2pp), Communication Services (-2.4pp).
Versus the prior quarter, Invenomic Capital Management LP opened 35 new positions, trimmed 31 and fully exited 35, a turnover rate of 66.9% of positions. The portfolio's overlap with the prior quarter was 67% of names.
The largest new positions opened in Q4 2025 were AZO ($54.26M), ORLY ($22.73M), FISV ($19.30M).
Of the 35 positions fully exited versus the prior quarter, the largest were ARKK ($103.56M), SPY ($50.23M), HAE ($24.29M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q4 2025)
Fully Exited (vs previous quarter)
- ARKK ARK ETF TR · prev qtr: $103.56M
- SPY STATE STR SPDR S&P 500 ETF T · prev qtr: $50.23M
- HAE HAEMONETICS CORP MASS · prev qtr: $24.29M
- BKH BLACK HILLS CORP · prev qtr: $19.61M
- SEE SEALED AIR CORP NEW COM · prev qtr: $15.49M
- UHS UNIVERSAL HLTH SVCS INC · prev qtr: $14.98M · history
- GOLD GOLD COM INC · prev qtr: $13.44M
- KHC KRAFT HEINZ CO · prev qtr: $12.98M
Insider Transactions (Form 4)
Latest Invenomic Capital Management LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Invenomic Capital Management LP is an SEC-registered 13F filer based in Boston, MA, United States. As of Q3 2026 it reported 116 US equity positions with a combined value of $2.02B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).
Firm Snapshot
- Headquarters: BOSTON, MA, United States
- SEC registration: 801-110459 (status: Approved), registered 2017-04-20
- Regulatory AUM (Form ADV): $3.39B as of 2026-03-31
- Client mix (by RAUM): registered investment companies 60%, pension and profit-sharing plans 40%
- Manages 2 private funds, of which 2 hedge funds
Portfolio Structure
- 116 positions · $2.02B reported value (Q3 2026)
- Top 10 holdings = 29.4% of reported value
- Largest position: UHS (UNIVERSAL HLTH SVCS INC) at 3.9%
- Average position size: $17.43M
Sector Tilt
- Consumer Discretionary 28.5%
- Information Technology 26.1%
- Industrials 14.9%
- (classified holdings cover 98% of value)
Quarterly Activity
- Q3 2026: 35 new, 45 added, 31 reduced, 35 exited
- 5 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
5.59M | $69.64M | 3.24% | Add | |
| 2 |
|
797.50K | $61.73M | 2.87% | Add | |
| 3 |
|
5.13M | $58.66M | 2.73% | Add | |
| 4 |
|
671.57K | $58.59M | 2.73% | Add | |
| 5 |
|
16.00K | $54.26M | 2.53% | New | |
| 6 |
|
1.50M | $53.75M | 2.50% | Reduce | |
| 7 |
|
3.31M | $47.00M | 2.19% | Add | |
| 8 |
|
1.54M | $44.42M | 2.07% | Add | |
| 9 |
|
652.97K | $43.76M | 2.04% | Add | |
| 10 |
|
3.03M | $42.51M | 1.98% | Add | |
| 11 |
|
346.56K | $42.29M | 1.97% | Reduce | |
| 12 |
|
1.22M | $40.53M | 1.89% | Add | |
| 13 |
|
708.91K | $38.66M | 1.80% | Add | |
| 14 |
|
871.44K | $38.03M | 1.77% | Add | |
| 15 |
|
455.67K | $36.80M | 1.71% | Add | |
| 16 |
|
874.24K | $36.35M | 1.69% | Add | |
| 17 |
|
174.51K | $35.16M | 1.64% | Add | |
| 18 |
|
11.96M | $32.65M | 1.52% | Add | |
| 19 |
|
9.03M | $30.16M | 1.40% | Add | |
| 20 |
|
737.55K | $29.94M | 1.39% | Add | |
| 21 |
|
2.38M | $27.27M | 1.27% | Add | |
| 22 |
|
2.44M | $26.81M | 1.25% | Add | |
| 23 |
|
629.45K | $26.63M | 1.24% | Add | |
| 24 |
|
331.17K | $24.41M | 1.14% | Hold | |
| 25 |
|
1.60M | $23.95M | 1.11% | Add | |
| 26 |
|
404.62K | $23.62M | 1.10% | Add | |
| 27 |
|
1.09M | $23.27M | 1.08% | Add | |
| 28 |
|
249.20K | $22.73M | 1.06% | New | |
| 29 |
|
1.54M | $22.64M | 1.05% | Reduce | |
| 30 |
|
1.44M | $22.04M | 1.03% | Add | |
| 31 |
|
1.68M | $20.96M | 0.97% | Add | |
| 32 |
|
1.72M | $20.89M | 0.97% | Add | |
| 33 |
|
1.05M | $20.29M | 0.94% | Reduce | |
| 34 |
|
756.72K | $20.16M | 0.94% | Add | |
| 35 |
|
1.40M | $20.10M | 0.94% | Add | |
| 36 |
|
557.61K | $19.60M | 0.91% | Add | |
| 37 |
|
386.05K | $19.57M | 0.91% | Add | |
| 38 |
|
287.27K | $19.30M | 0.90% | New | |
| 39 |
|
1.91M | $18.55M | 0.86% | Hold | |
| 40 |
|
2.13M | $18.47M | 0.86% | Hold | |
| 41 |
|
197.76K | $18.33M | 0.85% | Hold | |
| 42 |
|
163.76K | $18.33M | 0.85% | New | |
| 43 |
|
607.80K | $17.85M | 0.83% | Add | |
| 44 |
|
277.22K | $17.70M | 0.82% | Add | |
| 45 |
|
258.34K | $17.17M | 0.80% | Add | |
| 46 |
|
151.38K | $16.69M | 0.78% | New | |
| 47 |
|
653.51K | $16.44M | 0.77% | Add | |
| 48 |
|
678.23K | $16.34M | 0.76% | New | |
| 49 |
|
1.59M | $15.76M | 0.73% | Add | |
| 50 |
|
735.10K | $14.57M | 0.68% | Reduce | |
FAQ
What did Invenomic Capital Management LP buy in 2025-Q4?
In its 2025-Q4 13F filing, Invenomic Capital Management LP reported 147 equity positions worth $2.15B in aggregate; its largest disclosed positions were VTRS ($69.64M), GPN ($61.73M), XRAY ($58.66M).
How large is Invenomic Capital Management LP's portfolio?
Invenomic Capital Management LP reported $2.15B of long equity holdings across 147 positions as of 2025-Q4. Top-10 holdings account for 24.9% of reported value.
What is Invenomic Capital Management LP's investment style?
HoldingsHub classifies the portfolio as Mid / Diversified / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.